Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Non-Current Assets: 2010-2024

Historic Non-Current Assets for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $610.2 million.

  • Ligand Pharmaceuticals' Non-Current Assets rose 11.99% to $722.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $722.9 million, marking a year-over-year increase of 11.99%. This contributed to the annual value of $610.2 million for FY2024, which is 10.99% up from last year.
  • Ligand Pharmaceuticals' Non-Current Assets amounted to $610.2 million in FY2024, which was up 10.99% from $549.8 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Non-Current Assets high stood at $861.7 million for FY2020, and its period low was $499.1 million during FY2022.
  • For the 3-year period, Ligand Pharmaceuticals' Non-Current Assets averaged around $553.0 million, with its median value being $549.8 million (2023).
  • In the last 5 years, Ligand Pharmaceuticals' Non-Current Assets spiked by 132.10% in 2020 and then plummeted by 40.08% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Non-Current Assets (Yearly) stood at $861.7 million in 2020, then declined by 3.35% to $832.8 million in 2021, then tumbled by 40.08% to $499.1 million in 2022, then climbed by 10.16% to $549.8 million in 2023, then rose by 10.99% to $610.2 million in 2024.